证券代码：688399 证券简称：硕世生物 公告编号：2026-001 江苏硕世生物科技股份有限公司 获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 一、获得补助的基本情况 江苏硕世生物科技股份有限公司（以下简称"公司"）于近 日收到政府补助人民币163万元，属于与收益相关的政府补助。 二、补助的类型及其对上市公司的影响 根据《企业会计准则第16号－政府补助》的有关规定，公司 获得的上述政府补助属于与收益相关的政府补助。上述政府补助 未经审计，具体的会计处理及对公司2025年度损益的影响，最终 以审计机构年度审计确认后的结果为准，敬请投资者注意投资风 险。 特此公告。 江苏硕世生物科技股份有限公司董事会 2026 年 1 月 5 日 1 ...

Core Viewpoint - The in vitro diagnostic (IVD) sector is experiencing significant growth, with a notable increase in stock performance among key companies in the industry, driven by strong downstream demand and market expansion [1] Group 1: Market Performance - As of September 22, the IVD sector saw an overall increase of 3.13%, ranking high on the stock performance list [1] - Notable stock performances include: - Bohui Innovation reached a limit-up - Lide Man surged by 11.76% - Shuoshi Biology and Daan Gene increased by 9.17% and 9.01% respectively - Other companies like Dongfang Biology, Shengxiang Biology, Mingde Biology, BGI, Libang Instruments, and Wantai Biology also saw gains exceeding 6% [1] Group 2: Industry Growth - The IVD industry is primarily utilized in hospital laboratories, independent clinical laboratories (ICL), health check centers, epidemic prevention stations, and blood stations [1] - The downstream demand is robust, with IVD growth nearing 20% [1] - In 2018, the revenue from public hospitals for IVD products reached 315.7 billion yuan, with a year-on-year growth rate of 12.48% [1] - Key clients such as ICL and health check centers are also experiencing growth rates around 20% or higher [1] Group 3: Market Size and Comparison - The Chinese IVD industry size reached 71.3 billion yuan in 2018, reflecting a year-on-year growth of 25.6%, significantly outpacing the global IVD market growth of 6.0% [1] - The strong downstream demand is driving rapid growth in the upstream market size [1] - The IVD sector is nurturing large enterprises, and the favorable conditions in specific segments make leading stocks with performance support worth monitoring [1]

证券日报网讯12月25日，硕世生物在互动平台回答投资者提问时表示，公司高度重视国际化战略，积极 推进海外市场布局，加强与国际市场的合作，持续拓展海外业务版图。目前，公司产品已销往全球多个 国家和地区，其中包含欧盟成员国。 ...

Market Overview - The medical device sector increased by 1.35% on December 25, with Sainuo Medical leading the gains [1] - The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1] Top Performers - Sainuo Medical (688108) closed at 20.43, up 14.90%, with a trading volume of 609,800 shares and a transaction value of 1.22 billion [1] - Jinhao Medical (920925) closed at 33.03, up 12.81%, with a trading volume of 38,400 shares [1] - Mailland (688273) closed at 40.38, up 12.07%, with a trading volume of 54,800 shares [1] - Tianchen Medical (688013) closed at 52.94, up 11.10%, with a trading volume of 31,200 shares [1] - Xiangyu Medical (688626) closed at 57.47, up 6.80%, with a trading volume of 53,400 shares [1] Underperformers - C Jianxin (688805) closed at 53.31, down 8.28%, with a trading volume of 142,100 shares and a transaction value of 754 million [2] - Tianyi Medical (301097) closed at 51.89, down 5.43%, with a trading volume of 18,800 shares [2] - Hualan Co. (301093) closed at 49.54, down 2.75%, with a trading volume of 39,000 shares [2] Capital Flow - The medical device sector saw a net inflow of 137 million from institutional investors, while retail investors experienced a net inflow of 65.58 million [2] - The sector's main funds saw a net outflow of 203 million from speculative funds [2] Individual Stock Capital Flow - Sainuo Medical had a net inflow of 117 million from main funds, but a net outflow of 98.09 million from retail investors [3] - Zhend Medical (603301) had a net inflow of 85.32 million from main funds, with a net outflow of 76.17 million from retail investors [3] - Huakang Clean (301235) had a net inflow of 65.37 million from main funds, with a net outflow of 64.32 million from retail investors [3]

Core Viewpoint - The company has completed the repurchase and cancellation of shares, reflecting a strategic shift in the use of repurchased shares from employee incentives to cancellation [1] Group 1: Share Repurchase and Cancellation - The company announced the completion of share repurchase and cancellation on December 26, 2025, involving the cancellation of 168,903 shares [1] - The canceled shares represent 0.1715% of the total share capital prior to cancellation, which was 98,499,050 shares [1] - The funds used for this cancellation amounted to 10.9953 million yuan [1] Group 2: Changes in Capital Structure - Following the cancellation, the company's total share capital decreased from 98,499,050 shares to 98,330,147 shares [1] - The registered capital was adjusted from 98,499,050 yuan to 98,330,147 yuan as a result of the share cancellation [1] - The company plans to proceed with the necessary business registration changes following this cancellation [1]

格隆汇12月25日丨硕世生物(688399.SH)在投资者互动平台表示，公司高度重视国际化战略，积极推进 海外市场布局，加强与国际市场的合作，持续拓展海外业务版图。目前，公司产品已销往全球多个国家 和地区，其中包含欧盟成员国。 ...

Group 1 - The core viewpoint of the articles highlights a significant upward movement in the medical device sector, driven by policy changes and market dynamics, with a particular focus on the launch of the sixth batch of high-value medical consumables procurement [1][2] - The medical device index ETF (159898) saw a 1.29% increase, with substantial purchases of 36 million units during trading, indicating strong investor interest [1] - Key stocks within the sector, such as SINO Medical and Mailland, experienced notable gains, with increases exceeding 14% and 11% respectively, reflecting positive market sentiment [1] Group 2 - The sixth batch of national high-value medical consumables procurement is set to begin on January 13, 2026, introducing new mechanisms to prevent malicious low pricing, including the concept of anchor pricing and a multi-revival mechanism [1] - The National Medical Products Administration has released new regulations to support medical device exports, which will take effect on May 1, 2026, aimed at optimizing the process for obtaining export sales certificates [1] - Northeast Securities predicts that 2026 will be a year of value reconstruction for the Chinese medical device sector, driven by improved cash flow in hospitals and expectations of policy optimization [2]

12月24日硕世生物大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 溢价（%） | | | | 5.88 | 373.38 | 63.50 | -6.08 | 平安证券股份有限公 | 华西证券股份有限公 | | | | | | 司山东分公司 | 司济南分公司 | 硕世生物12月24日大宗交易平台出现一笔成交，成交量5.88万股，成交金额373.38万元，大宗交易成交 价为63.50元，相对今日收盘价折价6.08%。该笔交易的买方营业部为平安证券股份有限公司山东分公 司，卖方营业部为华西证券股份有限公司济南分公司。 （文章来源：证券时报网） 两融数据显示，该股最新融资余额为3.25亿元，近5日增加408.82万元，增幅为1.27%。 据天眼查APP显示，江苏硕世生物科技股份有限公司成立于2010年04月12日，注册资本8387.1721万人 民币。（数据宝） 进一步统计，近3个月内该股累计发生3笔大宗交易，合计成交金额为1014.4 ...

12月24日，硕世生物大宗交易成交5.88万股，成交额373.38万元，占当日总成交额的4.27%，成交价63.5 元，较市场收盘价67.61元折价6.08%。 | 交易日期 -- 证券简称 | 蓬射代码 -- | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | | 卖出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | | 025-12-24 硕世生物 | 688399 | 63.5 373.38 | 5.88 | 买客证券受贸易限 | 去蘭景需劈毀為興 | KO | ...

2026 年 1 月 5 日 江苏硕世生物科技股份有限公司 2026 年第一次临时股东会会议材料 江苏硕世生物科技股份有限公司 江苏硕世生物科技股份有限公司 2026 年第一次临时股东会会议材料 证券简称：硕世生物 证券代码：688399 江苏硕世生物科技股份有限公司 2026 年第一次临时股东会 会议材料 2026 年第一次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证会 议的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市 公司股东会规则》以及《江苏硕世生物科技股份有限公司章程》《江苏硕世生物 科技股份有限公司股东会议事规则》等相关规定，特制定 2026 年第一次临时股 东会须知。 一、为保证本次会议的严肃性和正常秩序，切实维护与会股东（或股东代理 人）的合法权益，除出席会议的股东（或股东代理人）、公司董事、高级管理人 员、见证律师及董事会邀请的人员外，公司有权依法拒绝其他无关人员进入会场。 二、出席会议的股东及股东代理人须在会议召开前半小时到会议现场办理签 到手续，并按规定出示证券账户卡、身份证明文件或营业执照复印件（加盖公章）、 授权委托书等， ...